Drug-induced liver injuries in pregnancy in the context of polypragmasy
Abstract
Pregnancy is characterized by overexertion of metabolism in the liver and some changes in metabolism, which can lead to various, including severe organ, damage. During pregnancy, according to international epidemiological studies, more than 80 % of women take medicines. Under polypragmasy it is extremely difficult to isolate a particular medicine responsible for the drug pathology in the liver in pregnant women. The article presents a retrospective analysis of spontaneous reports accepted from the Russian database of AIS Roszdravnadzor for the period from 01.01.2009 to 31.12.2016.
Keywords
беременность,
лекарственный гепатит,
поливитамины,
гестагены,
спонтанные сообщения,
российская база АИС Росздравнадзор «Фармаконадзор»,
безопасность лекарственных средств,
pregnancy,
drug-induced hepatitis,
multivitamins,
gestagens,
spontaneous reports,
Russian AIS database Roszdravnadzor Pharmacovigilance,
drug safety
About the Authors
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
K. E. Zatolochina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
O. S. Alyautdina
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Volkova L, Alyautdina O, Paltsev M, Paltseva E. Evaluation of the state of the vascular endothelium in various obstetric pathologies. The Doctor 2011; (5): 86–7 (in Russian).
2. Nikolaeva AV, Murashko LE, Nikolaeva AV, Fedorova TA, Khodova SI. Pregnancy and delivery outcomes in women with intrahepatic cholestasis of pregnancy: XVIII FIGO WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS. 2006; P. 50 (in Russian).
3. Eremina EY. Medicinal hepatitis in pregnant women. Problems of Women’s Health 2011; 6(4): 46–55 (in Russian).
4. Czeizel AE. Epidemiological studies of congenital abnormalities in Hungary. Issues and reviews in teratology. Ed. H. Kalter-Dordrecht: Kluwer Academic Publishers 2000; 85–124.
5. Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur. J. Clin. Pharmacol. 2000; 56(4): 323–328.
6. Tkacheva HE, Bevz AY, Ushkalova EA, Chukharev NA. The first All-Russian pharmacoepidemiological study «Epidemiology of drug use in pregnant women»: the main results. Obstetrics and Gynecology 2001; (4): 112–117(in Russian).
7. European Medicines Agency. Announcement of European Medicines Agency priorities for drug Reaction research. — London, 4 August 2009 [Electronic source]. Doc. Ref. EMEA/497624/2009. (cited 20.03.2017). Available from: http://www.ema.europa.eu/pdfs/human/phv/49762409en.pdf.
8. FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy. For Immediate Release: Dec. 30, 2009. [Electronic source]. (cited 02.05.2017). Available from: https://goo.gl/DfESA1.
9. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet. And Gynecol 2002; 100: 465–473.
10. Alautdin RN. PHARMACOLOGY. ULTRA LIGHT: a study guide. M.:GEOTARmedia; 2012 (in Russian).
11. Medical Department of GlaxoSmithKline Biologicals. Use of vaccines during pregnancy. BIO preparations. Prevention, diagnosis, treatment 2010; 2(38): 6–8 (in Russian).
12. Sokova EA, Bunyatyan ND, Maserkina IA, Demidova OA, Aleksandrova TV. Clinical studies of medicines in pregnant women: the ratio of expected benefits to possible risks? The Scientific Center for Expertise of Medical Applications 2015; (4): 26– 31(in Russian).
13. Gerasimenko AV, Eremina EY, Gerasimenko IV, Chernova OV. Features of medicinal liver damage in pregnant women. Diary of the Kazan Medical School. 2013 [Electronic source]. (cited 05.05.2017). Available from: https://goo.gl/h4r8Fs (in Russian).
14. Kuznetsova AI. Is prolonged vitaminization of pregnant women justified? Bull. FTSKE them. V. A. Almazova. Theses 6 Interdisciplinary Conv. On obstetrics, perinatology and neonatology «Healthy woman — a healthy newborn» 2011; 64 (in Russian).
15. Prilepskaya VN, Kutueva FR, Kuleshov VM, Andreeva MD, Tkachenko LV, Zaitseva TD, Pogodina TA. Results of the Russian non-interventional (observational) program for the prescription of a vitamin and mineral complex for the prevention of hypovitaminosis and mineral deficiency «PROGNOSTIC» in pregnant women. Gynecology 2016; 04: 5–11(in Russian).
16. Bukatina TM, Pasternak EY, Romanov BK, Alyautdin RN, Lepakhin VK, Kazakov AS, Zatolochina KE, Snegireva AI, Darmostukova MA, Kolesnikova EYu, Zhuravleva EO, Velts NYu, Kutekhova GV. Information about the decisions of foreign regulatory bodies. Safety and risk of pharmacotherapy 2016; (2): 40–41 (in Russian).
17. Shekhar G. Diddi. Liver disease in pregnancy. Taiwanese Journal of Obstetrics & Gynecology 2015; (54): 475–482.
18. Abu-Hayyeh S, Papacleovoulou G, Lovgren-Sandblom A, Tahir M, Oduwole O, Jamaludin NA, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. HEPATOLOGY 2012; 57: 716–726.
19. Abu-Hayyeh S, Martinez-Becerra P, Sheikh Abdul Kadir SH, Selden C, Romero MR, Rees M, et al. Inhibition of Na1-taurocholate co-transporting polypeptide- mediated bile acid transport by cholestatic sulfated progesterone metabolites. J Biol Chem 2010; 285: 16504–16512.
20. Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans- inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006; 44: 1150– 1157.
21. Zhuravleva EO, Velts NYu, Zatolochina KE, Darmostukova MA, Lepakhin VK, Romanov BK, Alyautdin RN, Glagolev SV, Polivanov VA. Analysis of spontaneous reports of adverse reactions that develop with the use of drugs during pregnancy. Safety and risk of pharmacotherapy 2017; (2): 61–69 (in Russian).
22. Romanov BK. Kal’tsievaya regulyatsiya aktivnosti lizosomal’nykh fermentov miokarda. Biomedical chemistry 2005; 51 (6): 634–642 (in Russian).
23. Kondrackienë J, Kupèinskas L. Liver diseases unique to pregnancy. Medicina. 2008; 44: 337–341.
24. Cochrane Collaboration Pregnancy and Childbirth Database. [Internet]. 2017 [cited 23 Jan 2017]. Available from: http://pregnancy.cochrane.org/.
Review
For citations:
Velts N.Yu., Zhuravleva E.O., Darmostukova M.A., Zatolochina K.E., Alyautdina O.S. Drug-induced liver injuries in pregnancy in the context of polypragmasy. Safety and Risk of Pharmacotherapy. 2017;5(3):104-111. (In Russ.)
Views:
1327
Email this article 